Jubilant Life Sciences seeks nod to roll out remdesivir tablet

Jubilant Life Sciences seeks nod to roll out remdesivir tablet

Noida-based Jubilant Life Sciences reportedly plans to launch remdesivir in a tablet form. The antiviral drug, which is being used to treat COVID-19 patients, is currently administered intravenously. According to media reports, the company has sought permission of the Drugs Controller General of India (DCGI) to launch remdesivir in a tablet form. In a meeting held on August 25, the company had presented its proposal to the DCGI. The company has given bioavailability protocol to the subject expert committee (SEC), which has been set up to evaluate proposals related to COVID-19. According to the proposal, the company is exploring the possibility of launching 20-mg sublingual tablets. Sublingual administration involves placing a drug under the tongue so that it gets dissolved and absorbed into the blood through the tissues. The SEC, which functions under DCGI, has reportedly asked for more clarity from the company on the proposal.

 

Vinati plans Rs. 150-crore expansion in speciality chemicals geared at exports

Vinati plans Rs. 150-crore expansion in speciality chemicals geared at exports

Vinati Organics Ltd. (VOL) has announced a capital expenditure (capex of Rs. 150-crore) to produce four new speciality chemical products for agrochemicals, dyes and plastic additives industries, and expand its para-tertbutyl benzoic acid (PTBBA) capacity. The capex is expected to complete by FY21-end, and the company expects the projects to make a revenue contribution of Rs. 240-crore at its peak level. All four products are directed at the export market as there is no signifi cant demand in the domestic market. The strategy of introducing new products looks encouraging in the current scenario where VOL’s key product ATBS (60% of FY20 revenue) is struggling to fi nd demand. According to Emkay, an equity research fi rm, COVID-19 has dented demand for ATBS and resulted in a slower-than-expected ramp-up of the newly-commissioned Butylated Phenol (BP) plant. However, recovery in isobutyl benzene (IBB) volume should mitigate the affect of decline in ATBS sales. The fi rm expect benefi ts of the ramp-up in BP and incremental revenue from new products to result in a 20% sales CAGR in FY23. “We raise FY22/23E EPS by 2.7/7.7% on capex plans,” a report said. On a standalone basis, VOL’s net profi t fell 12.2% to Rs. 72.30-crore on 20.4% decrease in net sales to Rs. 231.57-crore in Q1 June 2020 over Q1 June 2019.

IOC to invest Rs. 1,268-crore for Needle Coker Unit at Paradip The Indian Oil Corporation (IOC) board has cleared the Stage-1 approval to install a grassroot Needle Coker Unit at Paradip Refi nery using IOC’s in-house technology. The proposed unit will have a Calcined Needle Coke (CNC) production capacity of 56-ktpa, and the estimated project cost is Rs. 1,268-crore. With the production of CNC, IOC shall enter this niche product segment for the fi rest time. CNC is used to produce graphite electrodes for deployment in the high temperature (2800°C) electric arc furnaces in the steel industry. It is a substitute for natural graphite and offers higher quality consistency. With these technological advancements, CNC is now used to make the carbon anode of lithium-ion batteries used in Electric Vehicles (EVs). “This Needle Coker Unit is yet another signifi cant step by IOC towards de-risking the uncertainty in the POL business. The proposed unit will enhance the Refi nery Gross Margin and will also demonstrate IOC’s capability of supplying indigenously licensed technology in niche product segments,” Mr. S.M. Vaidya, Chairman, IOC, said. Presently the entire CNC requirement of the country (80-100 ktpa) is met through imports. The project can also be replicated at other Indian Refi neries that process lowsulphur-feed in FCCU/RFCCU/INDMAX type of units as a GRM improvement initiative. BPCL launches certifi ed reference material for petroleum labs Bharat Petroleum Corporation Ltd. (BPCL) has launched the country’s fi rest certifi ed reference material for testing chemical components of crude oils. ‘Bhartiya Nirdeshak Dravya,’ the fi rest batch of the certifi ed reference material, is approved by the National Physical Laboratory, New Delhi, which is under the Ministry of Science and Technology. The reference material has a traceability to the International System of Units and is being produced at BPCL’s Sewree Laboratory in Mumbai, the company said in a statement. Reference materials are used to ensure that laboratory instruments perform properly, accurately, and to the standards of predefi ned value.

GSFC restarts methanol plant after six years of shut down

GSFC restarts methanol plant after six years of shut down

 Aiming to support import substitution, state-owned Gujarat State Fertilizers & Chemicals Limited (GSFC) has restarted its methanol plant after six years. With installed capacity of 525-tpd (tonnes per day), the plant was commissioned in 2013 and operated for 11 months before shutting down in April 2014 due to non-viability. However, now after over six years, GSFC has re-started the plant with methanol being produced from August 31, 2020 as per the prescribed specifi - cations and quality. According to the company, the plant is running smoothly and sales have started in the domestic market. The fi rest consignment of 30-tonnes was dispatched on August 31, even as the plant is likely to reach a daily production of 470-tonnes by September 10. Methanol is used in several industrial applications like formaldehyde, methyl amines, dyes & intermediates, paints, solvents, adhesives and pesticides, among other things. In the Indian market, however, the major application of methanol is in formaldehyde, which accounts for about 60% of methanol consumption. Currently, GNFC and RCF are the only two companies producing methanol in India. As a result, India’s demand for methanol is met by imports primarily from Middle East countries. With the resumption of its methanol plant, GSFC is estimating an additional turnover of Rs. 150-crore in the current fi nancial year, 2020-21.

Deepak Fertilizer Step in to E-commerce

 Deepak Fertilisers’ arm partners with e-commerce platform for home delivery of fertilisers Smartchem Technologies Ltd., a 100% subsidiary of Deepak Fertilisers and Petrochemicals Corporation Ltd. (DFPCL), has announced a partnership with AgroStar, an agri-input e-commerce platform, for doorstep delivery of fertilisers to farmers. “Since digitalisation is rapidly changing the way services and products are delivered to the consumers, this partnership will enable last-mile delivery of value-added, differentiated fertilisers directly to farmers’ doorsteps. Home delivery of fertilisers can currently be availed by farmers in Maharashtra & Madhya Pradesh, with plans to extend the scope to other geograThe COVID-19 pandemic and low mobile data cost has accelerated the adoption of e-commerce platforms even in rural regions, and this trend is swiftly catching up in the agricultural space and the farmers now have access to diverse choices beyond the traditional services.” Mr. Shardul Sheth, CEO and Co-Founder of AgroStar, said, “Getting access to good quality nutrients and knowing what to use when and how much is critical for farmers to increase their yield and improve the quality of their output. We are excited to collaborate with Smartchem Technologies to enable broader and deeper penetration of their products across multiple states that we operate in.” phies in the future,” a company release informed. Commenting on the development, Mr. Mahesh Girdhar, President, Crop Nutrition Business, DFPCL, said, “The new normal is all about focusing on obstacles and carving a way through them. 

LyondellBasell opens new pilot molecular recycling facility in Italy

LyondellBasell opens new pilot molecular recycling facility in Italy

LyondellBasell, one of the largest plastics, chemicals and refi Ning companies in the world, has announced thestart-upof its new ‘MoReTec’molecularrecycling facilitates Ferrara, Italy,site.Withthis new plant, the company aims to industrialise its proprietary recycling technology to return post-consumer plastic wastes to their molecular form for use as a feedstock for plastic materials. “Ending plastic waste in the environment and advancing the circular economy re key sustainability fo cu areas for our company,” said Mr. Jim Seward, LyondellBasell Senior Vice President of R&D, Technology and Sustainability. “With our advanced plastics recycling technology, we return larger volumes of plastic waste back into the value chain andproduce new materials  for high-quality applications, retaining their value for as long as possible.” The new plastic materials created by LyondellBasell’s ‘MoReTec’ technology can be used in food packaging and healthcare items, which must meet strictregulatory requirements. 

In July 2018, LyondellBasell an- nounced a collaborative effort with Germany’s Karlsruhe Institute of Technology (KIT) to advance its Molecular recycling efforts. This Collaboration proved the effi ciency of the ‘MoReTec’ Technology at laboratory scale and, in October 2019 the company announced The construction of the Ferrara pilot plant.The pilot plant is capable of processing Between 5 and 10 kilograms of household plastic waste per hour. 

The Pilot aims to understand the interaction of various waste types in the molecular recycling process, test the various catalysts, and confirm the process temperature and time needed to decompose the plastic waste into molecules. The goal is to have this completed over the next couple of years and then plan for an industrial scale unit.

Dr. Reddy’s settles patent suit with Celgene

 Dr. Reddy’s settles patent suit with Celgene

Dr. Reddy’s Laboratories Ltd. Has announced the settlement of its litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid(lenalidomide) capsules. In a settlement of

All outstanding claims in the litigation, Celgene has agreed to provide Dr.Reddy’swith a licence to sell volume-limited amounts of generic lenalidomidecapsulesin the US after March 2022 subject to regulatory approval. The agreed-upon percentages are cone dential,the Hyderabad-based company stated. Wellness business.” Remdesivir is an experimental antiviral drug developed by Gilead Sciences as a course of treatment for COVID-19. Gilead entered into anon-exclusive licensing agreement with Jubilant Life Sciences for distribution to127 countries. Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has entered an exclusive agreement with Saptagir Laboratories to manufacture remdesivir.

Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the US without volume limitation beginning On January 31, 2026. “We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” said Mr. Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. 

Saptagir Laboratories signs deal with Jubilant Generics to manufacture remdesivir

Saptagir Laboratories signs deal with Jubilant Generics to manufacture remdesivir

Hyderabad-based Saptagir Laboratories has entered into an agreement with Jubilant Generics to manufacture intermediates and Active Pharmaceutical Ingredient(API) for intravenous administered drug, remdesivir.

The drug will be produce davits Hyderabad WHO GMP certified sterile drug product manufacturing plant. Mr. Mahesh Reddy, Promoter & Chairman, Saptagir Group said, “Weave had several successes in product development in molecules that were previously only manufactured in China. This partnership meets the need of our multinational customers who approve India as a strong second source for products beyond China. With the new investment of Rs. 75-crores in the pharma plant at Hyderabad we will further grow our presence.

Kochi-based company to start phase 2b trials of COVID drug

Kochi-based company to start phase 2b trials of COVID drug

Kochi-based pharma company, PNBVesper Life, is all set to begin clinical trials for its experimental COVID-19drug, ‘PNB-001’. The company’s CEO Mr. P.N. Balaram said the company received approval from the Drug Controller General of India (DCGI) toconductphase 2b clinical trial of their

Proprietary drug. He said the moleculeiscapable of treating fever, body panhandling infection – conditions normally

associated with COVID-19.According to Mr. Balaram, the com-COLLABORATIONpany had proposed testing the drug on two sets of people – one that would consume only PNB’ proprietary drug and an other that would consume it along with other drugs to treat these other conditions.However,the government declined permission for it and, hence, the  clinical trials will be done on patients who will also be consuming other drugs

For their other conditions and symptoms. “This is the fi rest chemical entity in the phase 2 chemical trial in the world, “he said. “If it works, it will be a miracle molecule. We think it will give a much better effect than dexamethasone orany other steroids. This is also a very safe molecule because just a 100 mg capsule is required to get the effect on patients. We are planning to complete the whole phase-II clinical trial within60 days as the government is speeding up the approval process and recruiting patients may not be a big problem,” he said. The study will be conducted on40 COVID-19 patients at Pune’s BMJMedical College who are moderate patients on oxygen support.

RDIF ties up with Dr. Reddy’s for supply of Sputnik V in India

RDIF ties up with Dr. Reddy’s for supply of Sputnik V in India

The Russian Direct Investment Fund (RDIF), Russia’s Sovereign wealth fund, whichis sponsoring the ‘Sputnik V’ COVID-19 Vaccine developed by the Gamaleya Research Institute, Has tied up with Dr. Reddy’s Laboratories to conduct the clinical trials and distribution of the vaccine in India. Once the vaccine is approved by Indian regulators, Russia will supply 100 million doses, with deliveries beginning potentially as early as December. “India is among the most severely impacted countries from COVID-19, and we believe our human adenovirus dual vector platform will provide a safe and scientifi cally validated option to India in the battle against COVID-19,” RDIF’s CEO Mr. Kirill Dmitriev said  SURVEILLANCE & DISINFECTION in a statement. RDIF’s agreement with Dr. Reddy’s, unlike other foreign vaccine developers, covers only distribution, but the Russian sover- eign fund said it will also look for an Indian manufacturing partner. The agreement between RDIF and Dr. Reddy’s refl ects the growing awareness of countries and organisations to have a diversifi ed anti-COVID vaccine portfolio to protect their populations,” the fund said. It added that the platform of human adenoviral vectors has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences. “The Phase I and II results have shown promise, and we will  be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India,” said Mr.G.V. Prasad, CEO Dr. eddy’s in a statement. A study published in Lancet in September this year showed that the vaccine as safe and produced cellular as well as antibody response to the vaccine based on the phase 1 and 2 data. The data from phase 3 studies is expected to be published by October-November. Responding to the criticism that Russia was jumping timelines to get its vaccine out without following all the protocols, Mr. Dmitriev said that the adenovirus platform is much safer than the mRNA vaccines which most western companies are manufacturing.

HPCL plans three new labs at Bengaluru R&D center

HPCL plans three new labs at Bengaluru R&D centre

State-run Hindustan Petroleum Corporation Ltd. (HPCL) is developing three new labs at its R&D Centrein Bengaluru for research on petrochemicals, biofuels, batteries, hydrogen and solar energy, is Chairman and Managing Director, Mr. M.K. Surana, Informed shareholders at the company’s annual general meeting recently. Expansion of business portfolio with greater presence in the clean energy verticals of natural gas remains a focus area of the company, Mr. Surana said. HPCL, along with its joint ventures, has the authorisation for city gas distribution in 20 geographical areas covering nine states. To promote the usage of cleaner fuels and for giving wider choices to customers, CNG facilities were provided at 166 retail outlets taking the total number of CNG retail outlets to 471. 
 Mr. Surana reiterated previously announced plans that HPCL will invest over Rs. 60,000-crore in the next fi ve years for building infrastructure to support growth and expansion. This includes refi nery expansion and augmentation projects to increase capacity of Mumbai Refinery to 9.5-mtpa and Visakh Refi nery to 15-mtpa along with residue upgradation facilities. The project for setting up of 9-mtpa capacity greenfi eld refi nery-cum  etrochemical complex at Barmer in Rajasthan has made signifi cant progress with the award of EPC contracts for fi ve of the major process units out of total 13 process units.
HPCL is also looking to increase its presence in biofuels segment by building production facilities for second-generation (2G) ethanol and compressed biogas.

The Visakh refinery has commenced production of Very Low Sulphur Fuel Oil (VLSFO), with sulphur content less than .5%, to meet the global regulatory requirement for ocean-going vessels. HPCL said it is continuing to expand its footprint in overseas markets and plans to widen its presence to 20 countries. Pipeline network length and capacities are being augmented with three cross-country pipelines entailing an investment of about Rs. 5,600-crore, Mr.Surana added

IOC to set up Rs. 17,825-crore petrochemical unit in Gujarat refinery

IOC to set up Rs. 17,825-crore petrochemical unit in Gujarat refinery

Indian Oil Corporation (IOC) will invest Rs. 17,825-crore in its Gujarat refinery to boost its capacity to produce petrochemicals.
The Development is in line with the IOC’s strategy to facilitate petrochemical integration into its refi nery expansion plans, as this group of products is touted to be the biggest driver of oil demand in the long term.
The Gujarat refi nery upgrade is expected to be completed in 42 months. “The intention is to increase petrochemical intensity to insulate ourselves from the vagaries of auto fuel margin cracks and guarantee  better refi ning margins,” IOC chairman Mr. S.M. Vaidya said on September 21, while addressing the media after the company’s 61st Annual General Meeting.  IOC’s net profi t fell 47% annually to Rs. 1,910.8-crore in the quarter ended June 30,  mainly due to inventory losses stemming from fl uctuations in global oil prices. The petrochemicals business is expected to act as a cushion to its low-margin refi nery business. Mr. Vaidya added that though the company was revising the long-term demand scenario after the coronavirus crisis, it was on track to spend the Rs. 26,233-crore Capex earmarked for FY21. The company’s board has also recently approved the implementation of an integrated para-xylene (PX) and purifi ed terephthalic acid (PTA) complex project at its Paradip refi nery in Odisha, which would require an estimated investment of Rs. 13,805-crore. The project is expected to be completed by 2024. In the wake of a shift in energy usage patterns to address climate change and global  warming, IOC has been investing across the energy value chain in diverse areas such as renewables, electric mobility, bio-fuels and hydrogen. It has set up EV-charging and battery-swapping facilities in 76 and 11 retail outlets, respectively. The company also intends to set up a metal-air, battery-manufacturing facility and develop fuel cells and indigenous hydrogen storage solutions.

Govt. begins dumping probe on sodium hydrosulphite imports from China, South Korea

Govt. begins dumping probe on sodium hydrosulphite imports from China, South Korea

 

The Directorate General of Trade Remedies (DGTR), under the Commerce & Industry Ministry, has initiated an anti-dumping investigation related to import of sodium hydrosulphite, mainly used in textiles, soap and molasses making, from China and South Korea.

The investigation has been initiated following an application filed by Transpek-Silox Industry on behalf of domestic industry, as per an official notification. “The applicant has alleged that material injury is being caused to the domestic industry due to dumped imports from the subject countries and has requested for imposition of the anti-dumping.

COVID-19 offers opportunities for Indian textiles industry to grow exports

COVID-19 offers opportunities for Indian textiles industry to grow exports

Mr. Ravi Capoor, Secretary,
Ministry of Textiles, Govt. of India, has said that while COVID-19 has adversely affected global market conditions, it has also opened up new vistas for the Indian textile industry to gain market share of China in the developed world, especially the EU and the US.

Addressing the inaugural session of  he three-day ‘GLOBIZ –  Global Textile & Home Furnishing Expo’, organized By FICCI, Mr. Capoor said that this is a promising time for the textile 
industry in India due to strong consumption in the domestic market as well as growing demand for exports. “Various Countries are looking at Indian markets and it’s the time to gear up supply chains, quality and deliver  at the promised schedules,” he said.

 

   

 

 

Mr. Capoor also urged the industry to work towards tapping unexplored global markets. “We are concentrated on few markets only. We should expand into the markets where India was never  present and virtual shows like GLOBIZ can help do that.” Mr. Capoor urged all stakeholders,including FICCI, to plan an outreach programme in new areas like the LatinAmerica and Japan. “There are challenges in the apparel industry, but the home furnishing sector has the potential to almost double its exports within two years,” he noted. He added that the Textile Ministry is planning a ‘TextileIndia Fair’, which is expected to e attended by over 30,000 buyers from different countries.

Anti-dumping duty is only for a limited period of time

Anti-dumping duty is only for a limited period of time

A three Judge Bench of the Supreme Court, comprising of Justices Arun Mishra, Vineet Saran and S. Ravindra Bhat, have held that levy of antidumping Duty (ADD)  Can only be for a limited duration and not for later periods. The judgment dated September 1, 2020 was in the case of The Designated Authority & Ors. v. The Andhra Petrochemicals Ltd. (APL). 

In This case, APL had applied to the Government and sought the imposition of ADD on imports of n-butanol from Saudi Arabia into India. This led to the initiation of investigation by the Designated Authority (DA) by Notifi cation dated 02.09.2016. However, the DA was of the opinion that it is not appropriate to impose ADD and therefore, terminated the investigation under Rule 14(b) of Anti-Dumping Rules. Being aggrieved, APL fi led a Writ Petition in the Telangana High Court, challenging the orders of the DA on he ground that the exports from Saudi Arabia were not just casual exports, but aimed at capturing the Indian market, as the performance of the domestic industry during the period of January to March, 2016 was adverse in terms of profits and returns on investments. 

The Tlangana High Court directed the DA to initiate an investigation into the alleged dumping and consequent injury to the domestic industry. But the DA conducted investigation only for a limited period of time, i.e. three months. As a result, the High Court initiated suomoto contempt petition against the DA and passed an Order dated 22.07.2019 directing the Central Government to choose a substitute DA on the ground that he failed to enlarge the period of investigation, as per the High Court’s directions.

How Indian chemical industry struggles to reduce dependency on china

The Indian sector has long been dependent on China to imports.The industry expert believe that domestic production suppliers from US, EU, Japan, South Korea, South Africa and others can fill the space by the Chinese suppliers.

Indian chemical industry

In the case of chemicals, the best options come from India or South Korea, chemical players now see an excellent business opportunity for India.



Day 54 of India lock down a high dependency on china has one opportunity in India. The chemical industry a sector worth 1000cr. and covering more then 30000 commercial goods is struggling. 
Indian chemical industry is nothing without any help from china.Indian businesses can diversify their vendors and supply chains so that the overall risk.

This is particularly important when it comes to a situation like a pandemic, where much of the world is seeing large scale disruptions. Big players says he has alternative supplies from Europe and part of Asia such as Korea, Japan etc. The trick here is to have many suppliers to hedge your bets against large scale disruption. Also, as the Covid-19 virus progresses, different regions find themselves in different levels of lock down.

Opportunity :

Due to corona scare, the world will not rely on China alone now. When we talk to foreign customers, we get a sense that they have now started giving a hard look to Chinese supplies. They are now increasingly looking at alternate from china.
Many of our exhibitors have very good products, but they need some distributors or some type of agents here who can help them to grow their business.

The 'Make in India' campaign as one which is intended to produce in India for consumers across the globe. 
South African manufacturers to use the opportunity of growing their businesses by partnering with India.

Also Read : 

Allopathic drugs to treat coronavirus disease 

Allopathic drugs to treat coronavirus disease

Allopathic treatment 

Corona virus emerged in December 2019 and then spread rapidly worldwide. Scientists are endeavouring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19). Some promising results have been achieved thus far.

Antivirals including interferon α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol have been included in the latest version of the Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia.

The specific method for administration of IFN-α is vapor inhalation at a dose of 5 million U (and 2 mL of sterile water for injection) for adults, 2 times/day. The dosage of lopinavir/ritonavir is 400 mg/100 mg for adults, 2 times/ day. Ribavirin should be administered via intravenous infusion at a dose of 500 mg for adults, 2 to 3 times/ day in combination with IFN-α or lopinavir/ritonavir. Chloroquine phosphate is orally administered at a dose of 500 mg (300 mg for chloroquine) for adults, 2 times/ day. Arbidol is orally administered at a dose of 200 mg for adults, 3 times/day. The duration of treatment is no more than 10 days.

Favipiravir is a drug that attract attention. Favipiravir was approved for treatment of novel influenza.This drug is currently undergoing clinic trials in treating COVID-19.

Remdesivir is another potential drug for treatment of COVID-19. Animal experiments indicated that remdesivir can effectively reduce the viral load in lung tissue of mice infected with MERSCoV, improve lung function, and alleviate pathological damage to lung tissue.

Studies have also revealed some other drugs may have potential efficacy in treating COVID-19. One is darunavir, which is a second-generation of HIV-1 protease inhibitor.

Also read :
How to Corona Treatment from the Homeopathic + Ayurveda

Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 by Glenmark in India

Company estimates that the study would be completed by August 2020, Glenmark Pharmaceuticals has initiated Phase-3 clinical trials in India on antiviral drug Favipiravir, for which it received approval from India’s drug regulator DCGI in late April 2020. 

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals in India. 

Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule, if commercialised, will be marketed under the brand name ‘FabiFlu’ in India.

The data from these trials will point in a clearer direction with regard to COVID-19 treatment. Company’s effort is to launch a treatment for COVID-19 patients as soon as possible and control the spread of the pandemic. Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.

Also read : 

How to Corona Treatment from the Homeopathic + Ayurveda

How to Corona Treatment from the Homeopathic + Ayurveda

Top 2 treatment of corona :

Coronavirus is a common virus which causes colds, influenza-like symptoms and pneumonia. COVID-19 is a new strain which means fewer people already have immunity to it. It appears to have the most severe effect on the elderly and people with existing medical conditions – particularly those with respiratory problems. There are no standard scientific trials available for homeopathic, or ayurvedic treatment of this coronavirus strain.

Homeopathic Medicine -COVID – 19

Homeopathic medicines have been used extensively for flu-like symptoms and in epidemics around the world. If you decide to take a homeopathic medicine, this should be in addition to the various measures and should not be your only approach. Selection of the most appropriate homeopathic medicine is based on an individual’s unique symptoms. However, Gelsemium 30c and Bryonia 30c are commonly used for flu-like symptoms and have a long-established, traditional usage over many years.

The AYUSH ministry India recommended that homeopathic medicine Arsenicum album 30 could be taken empty stomach daily for three days as a prophylactic medicine against the infection. The Ayush Ministry declared Arsenicum Album-30 as a "preventive' against COVID-19. On the basis of research done by Dr Rajan Sankaran, has backed Camphor 1M as a potential medicine for COVID-19.

Ayurvedic Medicine -COVID – 19

Ministry of Ayush starts clinical trials for Ashwagandha and 4 other Ayurvedic herbs for coronavirus treatment. In a recent positive development, Ministry of Ayush, in collaboration with the Council of Scientific & Industrial Research (CSIR) has started clinical trials testing formulation of four important Ayurvedic herbs in fighting the novel coronavirus. The medicines under study include ashwagandha, guduchi, yasthimadhu, peepli and another formulated drug, 'Ayush 64'.

Also Read : 
Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 by Glenmark in India